DGI
CHRS icon

Disciplined Growth Investors’s Coherus Oncology CHRS Stock Holding History

Disciplined Growth Investors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-566,746
Closed -$782K – 67
2024
Q4 		$782K Sell
566,746
-199,562
-26% -$224K 0.01% 61
2024
Q3 		$797K Sell
766,308
-490,781
-39% -$673K 0.02% 63
2024
Q2 		$2.17M Buy
1,257,089
+1,152
+0.1% +$2.32K 0.04% 60
2024
Q1 		$3M Buy
1,255,937
+89,210
+8% +$220K 0.05% 59
2023
Q4 		$3.89M Sell
1,166,727
-16,899
-1% -$45.3K 0.08% 55
2023
Q3 		$4.43M Buy
1,183,626
+3,941
+0.3% +$18.2K 0.11% 56
2023
Q2 		$5.04M Buy
1,179,685
+14,173
+1% +$83.6K 0.11% 54
2023
Q1 		$7.97M Buy
1,165,512
+22,092
+2% +$171K 0.2% 52
2022
Q4 		$9.06M Buy
1,143,420
+11,324
+1% +$87.1K 0.23% 54
2022
Q3 		$10.9M Buy
1,132,096
+886,075
+360% +$8.97M 0.3% 53
2022
Q2 		$1.78M Buy
246,021
+1,100
+0.4% +$9.56K 0.05% 65
2022
Q1 		$3.16M Buy
244,921
+8,855
+4% +$113K 0.07% 66
2021
Q4 		$3.77M Sell
236,066
-218,358
-48% -$3.82M 0.08% 64
2021
Q3 		$7.3M Hold
454,424
– – 0.14% 63
2021
Q2 		$6.29M Buy
454,424
+45,581
+11% +$646K 0.12% 65
2021
Q1 		$5.97M Sell
408,843
-49,600
-11% -$842K 0.12% 63
2020
Q4 		$7.97M Sell
458,443
-13,771
-3% -$245K 0.15% 63
2020
Q3 		$8.66M Buy
+472,214
New +$8.78M 0.2% 60

Other funds holding CHRS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Disciplined Growth Investors's CHRS Position: Q1 2025 in Review

Disciplined Growth Investors sold out of Coherus Oncology (CHRS) in Q1 2025, closing a stake of 566,746 shares — an estimated $782K sold.

Disciplined Growth Investors first reported a position in CHRS in Q3 2020 and held it in 18 quarters. The position peaked at $10.9M in Q3 2022. 117 funds tracked by Wall St. Rank hold CHRS as of Q1 2025.

  • Disciplined Growth Investors reported no remaining Coherus Oncology position as of Q1 2025 after selling out during the quarter.
  • Disciplined Growth Investors sold 566,746 Coherus Oncology shares in Q1 2025, an estimated $782K.
  • Disciplined Growth Investors first reported a position in Coherus Oncology in Q3 2020 and held it in 18 quarters.
  • Disciplined Growth Investors's Coherus Oncology position peaked at $10.9M in Q3 2022.
  • 117 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2025.

Based on Disciplined Growth Investors's 13F filing for Q1 2025, filed 15 May 2025.